Differential Diagnosis of Epithelioid Malignant Mesothelioma With Lung and Breast Pleural Metastasis: A Systematic Review Compared With a Standardized Panel of Antibodies-A New Proposal That May Influence Pathologic Practice

• Published in: Archives of pathology & laboratory medicine (1976) Vol. 144; no. 4; pp. 446 - 456
• Main Authors: Le Stang, Nolwenn, Burke, Louise, Blaizot, Gaetane, Gibbs, Allen R, Lebailly, Pierre, Clin, Bénédicte, Girard, Nicolas, Galateau-Sallé, Françoise
• Format: Journal Article
• Language: English
• Published: United States College of American Pathologists 01.04.2020
• Subjects: Adenocarcinoma - diagnosis; Antibodies; Antigens; Biological markers; Biomarkers; Biomarkers, Tumor - analysis; Biopsy; Breast; Breast cancer; Breast Neoplasms - diagnosis; Breast Neoplasms - secondary; Calretinin; Cancer; Cancer metastasis; Carcinoma; Cloning; Diagnosis; Diagnosis, Differential; Differential diagnosis; Estrogen receptors; Estrogens; Female; Handbooks; Health aspects; Humans; Immunoglobulins; Immunohistochemistry - methods; Keratin; Lung Neoplasms - diagnosis; Lung Neoplasms - pathology; Medical diagnosis; Mesothelioma; Mesothelioma - diagnosis; Mesothelioma - pathology; Mesothelioma, Malignant; Metastases; Metastasis; p53 Protein; Phenols (Class of compounds); Pleural Neoplasms - diagnosis; Pleural Neoplasms - secondary; Sensitivity and Specificity; Setting (Literature); Systematic review; Task forces; Thyroid gland; Transcription factors; Tumors; France; New York; United States > US
• ISSN: 0003-9985; 1543-2165; 1543-2165
• DOI: 10.5858/arpa.2018-0457-OA

Pleural mesothelioma is a rare cancer with an often-challenging diagnosis because of its potential to be a great mimicker of many other tumors. Among them, primary lung and breast cancers are the 2 main causes of pleural metastasis. The development and application of targeted therapeutic agents have made it even more important to achieve an accurate diagnosis. In this setting, international guidelines have recommended the use of 2 positive and 2 negative immunohistochemical biomarkers. To define the most highly specific and sensitive minimum set of antibodies for routine practice to use for the separation of epithelioid malignant mesothelioma from lung and breast metastasis and to determine the most relevant expression cutoff. To provide information at different levels of expression of 16 mesothelial and epithelial biomarkers, we performed a systematic review of articles published between 1979 and 2017, and we compared those data to results from the Mesothelioma Telepathology Network (MESOPATH) of the standardized panel used in routine practice database since 1998. Our results indicate that the following panel of markers-calretinin (poly)/thyroid transcription factor 1 (TTF-1; clone 8G7G3/1) and calretinin (poly)/estrogen receptor-α (ER-α; clone EP1)-should be recommended; ultimately, based on the MESOPATH database, we highlight their relevance which are the most sensitive and specific panel useful to the differential diagnosis at 10% cutoff. Highlighted by their relevance in the large cohort reported, we recommend 2 useful panels to the differential diagnosis at 10% cutoff.